NASDAQ$PMVP

Pmv Pharmaceuticals Inc · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

PMV Pharmaceuticals reported Q4 2024 a net loss of $58.7M.

For Q4 2024, PMV Pharmaceuticals reported net loss was $58.7M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.

  • Net loss $58.7M.
  • MD&A highlights operating priorities, liquidity, and sector risks.
  • MD&A highlights operating priorities, liquidity, and sector risks.

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS (adj)

-$0.45

Previous: -$0.31-45.2%
Capital Expenditures

-$56K

Previous: -$197K+71.6%
Free Cash Flow

-$16.7M

No prior period
Net Income

-$58.7M

Previous: -$15.8M-272.6%
Operating Income

-$25.2M

Previous: -$18.9M-33.1%
Gross Profit

-$39K

Previous: -$359K+89.1%
R&D Expense

$13.7M

Previous: $13M+5.4%

Revenue & EPS history

PMV Pharma · Revenue · Quarterly

$0

Q4 2024

Forward guidance

Outlook tied to clinical milestones, partnerships, and funding runway.

Tailwinds

  • Pipeline progress and collaboration economics.
  • Cash supports near-term operating plans.

Headwinds

  • Operating losses until commercial scale.
  • Trial and regulatory outcomes affect funding needs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+2.7%

Avg return

Earnings day

+3.4%

Avg return

5 days after

-1.3%

Avg return

30 days after

67%

14 / 21 earnings

Positive

+29.5%

Q2 2023

Best reaction

-18.1%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+2.0%+8.0%-10.7%
Q3 2025+8.5%+6.8%-7.5%
Q2 2025-4.1%-6.6%-3.9%
Q1 2025+4.2%+7.5%+28.9%
Q4 2024-3.6%-10.2%-27.0%
Q3 2024+4.8%+0.6%-4.2%
Q1 2024-5.6%-0.9%-23.1%
Q4 2023+3.9%+3.9%-6.1%
Q3 2023+7.5%+19.9%+24.2%
Q2 2023+29.5%+20.0%-10.8%
Q1 2023+11.9%+14.7%+8.5%
Q4 2022-18.1%-19.6%-33.8%
Q3 2022-3.7%+11.2%-2.6%
Q2 2022+0.4%-1.3%-17.6%
Q1 2022+2.2%+9.0%-13.7%
Q4 2021+10.3%+1.3%+31.4%
Q3 2021+0.4%+2.4%-1.6%
Q2 2021-1.2%-5.2%-10.2%
Q1 2021+12.7%+15.6%+18.5%
Q4 2020+0.7%-0.7%-5.9%
Q3 2020-5.1%-5.2%+40.3%
Q2 2020
Q1 2020
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro